Management of Candiduria in Catheterized Patients
The first and most critical step is to remove the indwelling urinary catheter if feasible, and in most cases, antifungal treatment is NOT recommended unless the patient is at high risk for dissemination (neutropenic, very low birth weight infant <1500g, or undergoing urologic manipulation). 1
Initial Assessment and Risk Stratification
The presence of Candida in urine with a catheter typically represents colonization rather than true infection. The key is identifying which patients actually need treatment:
Patients Who DO NOT Need Antifungal Treatment:
- Asymptomatic catheterized patients (the vast majority)
- Those without high-risk features
- Simply removing the catheter clears candiduria in approximately 50% of cases 2
Patients Who REQUIRE Treatment:
- Neutropenic patients - treat as candidemia 1
- Very low birth weight infants (<1500g) - treat as candidemia 1
- Patients undergoing urologic procedures - prophylactic treatment 1
- Symptomatic patients with cystitis or pyelonephritis (after catheter removal/replacement)
Treatment Algorithm
Step 1: Remove or Replace the Catheter
This is strongly recommended and should be done whenever feasible 1. Catheter removal alone often resolves candiduria without antifungals.
Step 2: Species Identification and Susceptibility Testing
Recent data shows concerning fluconazole resistance rates, particularly with C. glabrata (51% of isolates in one ICU study) 3. Speciation is crucial as it directly impacts treatment selection.
Step 3: Antifungal Selection (for patients requiring treatment)
For Symptomatic Cystitis:
Fluconazole-susceptible species (C. albicans):
- Oral fluconazole 200 mg (3 mg/kg) daily for 2 weeks 1
- This is a strong recommendation with moderate-quality evidence
Fluconazole-resistant C. glabrata:
- Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days OR
- Oral flucytosine 25 mg/kg four times daily for 7-10 days 1
- Alternative: Amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) may be useful 1
C. krusei:
- Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days 1
For Symptomatic Pyelonephritis:
Fluconazole-susceptible species:
- Oral fluconazole 200-400 mg (3-6 mg/kg) daily for 2 weeks 1
Fluconazole-resistant C. glabrata:
- Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days with or without flucytosine 1
For Patients Undergoing Urologic Procedures:
Prophylactic treatment several days before and after:
- Oral fluconazole 400 mg (6 mg/kg) daily OR
- Amphotericin B deoxycholate 0.3-0.6 mg/kg daily 1
Critical Pitfalls to Avoid
1. Overtreatment of Asymptomatic Patients
Studies show this is extremely common in clinical practice 4, 5. Approximately 23-24% of candiduria cases are managed inappropriately, with most errors being unnecessary treatment of asymptomatic colonization.
2. Using Inappropriate Antifungals
- Do NOT use echinocandins (caspofungin, micafungin, anidulafungin) for urinary tract infections - they achieve inadequate urine concentrations 1, 2
- Do NOT use lipid formulations of amphotericin B - they do not achieve adequate urine levels 1
- Only amphotericin B deoxycholate (not liposomal) is effective for urinary candidiasis
3. Ignoring Catheter Management
Treatment without catheter removal/replacement often fails. The catheter serves as a nidus for biofilm formation that antifungals cannot penetrate effectively 6.
4. Misinterpreting Diagnostic Tests
- Pyuria cannot differentiate infection from colonization in catheterized patients 1
- Colony counts are unreliable with catheters in place 1
- Clinical symptoms and risk factors are more important than laboratory values
Special Considerations
Fluconazole Treatment Failure: Recent data shows 50% treatment failure rates in symptomatic candiduria patients treated with fluconazole 3. This underscores the importance of:
- Species identification before treatment
- Susceptibility testing, especially in ICU patients
- Considering alternative agents for resistant species
Mortality and Outcomes: While adherence to guidelines doesn't significantly impact mortality 4, 5, proper management prevents unnecessary antifungal exposure and reduces selection pressure for resistant organisms. One study noted a patient developing candidemia shortly after acquiring candiduria 3, highlighting the importance of monitoring high-risk patients.
Duration of Catheterization: Risk increases substantially with prolonged catheterization 7. Nearly all patients with long-term catheters develop bacterial or fungal colonization 6.